Cannabis Report
Home > Boards > US OTC > Medical - Healthcare >

Dermisonics (DMSI)

Add DMSI Price Alert      Hide Sticky   Hide Intro
Moderator: Goodbuddy4863, pennystockwallstreet, justbecause516, mojomn, OTC_Buyer, Patient shareholder
Search This Board: 
Last Post: 6/21/2018 6:13:47 PM - Followers: 24 - Board type: Free - Posts Today: 0

US Address Dermisonics, Inc. 2 Park Plaza, Suite 450 Irvine, California 92614 TOLL-FREE: +1-888-401-DERM (3376) Tel: +1-949-733-1101 Fax: +1-949-266-8426 =============================================================== North American Investor Relations Contact: International Marketing Trend, Inc. Phone: 877-676-4447 European Investor Relations Contact: Michael Drepper Phone: +49-621-430-6130 =============================================================== Dermisonics is an advanced technology incubator thatis primarily focused on developing and marketing its transdermal and subdermal technologies for applications in the drug (U-Strip), skin care (U-Wand), and antiseptic (A-Wand) fields. Its breakthrough system, called the U-Strip, facilitates the efficient and needle-free delivery of drugs with large molecular structures into the bloodstream. In a radical departure from heretofore unsuccessful “needle-free injections” attempted in the past, Dermisonics’ technology is based on the use of ultrasonic impulses of variable intensity and frequency delivered to and through a unique drug patch that enlarges the skin’s pores and pushes drugs into the bloodstream, bypassing the potentially harmful effects of the human digestive system. Needle-Free Injections - Tests have shown that the U-Strip facilitates the transdermal delivery of Insulin as well as potentially at least 175 other existing drugs through the pores of the skin. Conventionally available transdermal technology cannot effectively deliver these drugs due to their large molecular size. Based on this technology, the Company has also developed major line extensions for applications in the medical (A-Wand) and skin care (U-Wand) fields. =============================================================== Dermisonics Develops Working Model of Antiseptic Wand Monday February 6, 7:18 pm ET In Talks With U.S. Army to Build Battlefield Version WEST CONSHOHOCKEN, Pa., Feb. 6 /PRNewswire-FirstCall/ -- Dermisonics, Inc. (OTC Bulletin Board: DMSI.OB - News), a pioneer in the development of ultrasonic transdermal drug-delivery technologies, announced today that it has completed the first working model of its A-Wand antiseptic delivery system and is in talks with the Army Institute of Surgical Research under the Combat Casualty Care Research Program to develop a battlefield version. ADVERTISEMENT The A-Wand (TM) is a handheld, portable, ultrasonic wand device for applying antiseptic solutions to cuts, abrasions and wounds with a replaceable Patch-Cap (TM), which holds up to 40 ml of antiseptic solution. It uses alternating ultrasonic waveforms to enlarge the diameter of the skin pores enabling antiseptics to permeate through the skin (Stratum Corneum) into the dermis through the sweat pores. Attacks Critical Problem of Infections in Wounded Soldiers -- Infection is a major, potentially lethal, battlefield hazard for wounded soldiers before they can receive full medical treatment in a hospital. The Medic on the scene applies antiseptic and bandages the wound but the antiseptic only affects the outermost layers of the damaged tissue. Infection frequently results and is a major cause of amputations. The A-Wand Encapsulates the Wounded Area with Antiseptic -- The A-Wand would be used by Medics in the field, by Mash units and for follow-up wound care to significantly reduce this hazard. Through the use of the A-Wand's ultrasound system, the antiseptic solution is "pushed" to the deeper tissue where it can more effectively fight infection by surrounding and encapsulating the wounded area with antiseptic. It also has the added advantage of being able to penetrate scared tissue without damaging this basic body defense system. Technology inventor and Dermisonics Executive Vice-President Bruce Redding commented, "The A-Wand represents a huge opportunity for Dermisonics and the various patients who could benefit from increased infection-resistant technologies. Dermisonics especially is pleased by the response from the US Army and we hope this technology finds acceptance in the field as soon as possible" The Next Generation in the $1.2 Billion Wound Care Market -- The Company believes the A-Wand will represent a significant shift in wound-care medical science and will fundamentally change the $1.2 billion wound-care market. Industry Opportunity and Receptivity -- As a harbinger of its immediate industry impact, the Company has already received, in addition to the military, strong indications of interest from major companies in the pharmaceutical and hospital fields. About Dermisonics, Inc. -- Dermisonics is an intellectual property company and advanced technology incubator that is primarily focused on the ongoing development, testing and eventual commercialization of a transdermal patch that has been designed to facilitate the efficient and needle-free delivery of drugs with large molecular structures into the bloodstream. Its breakthrough system, called the U-Strip, is based on a radical integration of microelectronics and ultrasonic science with a product-carrying patch and represents a quantum leap in non-invasive, transdermal delivery technology. Tests have shown that this system facilitates the transdermal delivery of insulin as well as potentially at least 175 other existing drugs that at present cannot be effectively delivered through the pores of the skin using conventionally available transdermal technology due to their large molecular size. The Company has also developed other portable ultrasonic systems for applications in the medical (Antiseptic Wand) and skin care (U-Wand) fields. ================================================================ Info from January 2007 A/S = 100,000,000 Shares Outstanding: 46.15M Restricted approx 25 million Float: 26.29M =============================================================== Daily Chart:
Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#360   I love the $.01 share price and no Goodbuddy4863 06/21/18 06:13:47 PM
#359   DMSI - I agree pennystockwallstreet 06/09/18 12:12:50 PM
#358   Excellent post! Could be some easy big money Patient shareholder 06/08/18 07:02:04 PM
#357   DMSI...easy money both short and Long term. Goodbuddy4863 06/05/18 05:27:43 PM
#356   The share structure is the reason I bought easymonee 05/27/18 02:10:03 AM
#355   I will agree it floats very well and OTC_Buyer 05/25/18 11:02:55 PM
#354   Holding from last year looking another 50k to easymonee 05/25/18 10:32:07 PM
#353   Are you still holding onto it from last OTC_Buyer 05/25/18 09:12:24 PM
#352   It was me adding today I will continue easymonee 05/24/18 08:23:21 PM
#351   DMSI 300% move on 30K vol? Looks Mark 05/24/18 07:50:29 PM
#350   I see and understand “a little now” on moneybags888 05/21/18 07:20:10 PM
#349   Good morning. Hope you had a great weekend also. DMSI Patient shareholder 05/21/18 10:27:11 AM
#348   Good morning DMSIers hope everyone had a great weekend. justbecause516 05/21/18 09:42:09 AM
#347   DMSI - I understand. Will update when pennystockwallstreet 05/21/18 08:41:05 AM
#346   Yes congratulations to Mojomn and thank you PSWS, moneybags888 05/21/18 12:10:27 AM
#345   Yes indeed..should start sometime in 2018. Goodbuddy4863 05/20/18 10:13:55 PM
#344   Excellent. In my opinion it seems DMSI will Patient shareholder 05/20/18 08:41:42 PM
#343   WOW...All the slots are filled now. Goodbuddy4863 05/20/18 08:19:53 PM
#342   Congrats on the mod spot mojomn. Welcome to DMSI Patient shareholder 05/20/18 08:17:09 PM
#341   Welcome aboard. Goodbuddy4863 05/20/18 07:50:12 PM
#340   Can't pay attention to otcmarkets on this one. Goodbuddy4863 05/20/18 07:42:23 PM
#339   Thanks now lets see mgmt start to make mojomn 05/20/18 07:37:23 PM
#338 mick 05/20/18 07:20:17 PM
#337   Yes indeed. Goodbuddy4863 05/20/18 07:14:59 PM
#336   reading some information $DMSI mick 05/20/18 06:50:10 PM
#335   anything on this one ????? 'Dermisonics (DMSI)' mick 05/20/18 06:49:25 PM
#334   Dermisonics, Inc. (P (DMSI) mick 05/20/18 06:48:10 PM
#333   READING 'Dermisonics (DMSI)' mick 05/20/18 06:47:56 PM
#332   DMSI - Congratulations to Mojomn on becoming a pennystockwallstreet 05/20/18 06:28:19 PM
#331   Looks like we have a new admin. Lets mojomn 05/20/18 06:14:49 PM
#330   Yes, thinking about adding here easymonee 05/19/18 11:51:03 PM
#329   10-4 Pal Goodbuddy4863 05/19/18 05:19:16 PM
#328   Agreed something from the company will tell the tale mojomn 05/19/18 04:50:12 PM
#327   I believe there are behind the scenes Happenings Goodbuddy4863 05/19/18 03:14:00 PM
#326   DMSI - Yes it is a great development. pennystockwallstreet 05/19/18 01:34:28 PM
#325   Welcome aboard Mojomn. Patient shareholder 05/19/18 01:32:22 PM
#324   This is a great development mojomn 05/19/18 12:59:38 PM
#323   Looking real good so far. Goodbuddy4863 05/19/18 12:06:25 PM
#322   Yes..I was looking at that..but My eyesight is Goodbuddy4863 05/19/18 12:00:51 PM
#321   WOW...most all My buddies are here. Goodbuddy4863 05/19/18 11:59:39 AM
#320   This is better than waiting for the Blockchain Goodbuddy4863 05/19/18 11:58:28 AM
#319   I am going to do a little research Patient shareholder 05/19/18 11:54:41 AM
#318   Yes...I am liking what I am reading there. Goodbuddy4863 05/19/18 11:54:03 AM
#317   Welcome to the new mod Goodbuddy at DMSI Patient shareholder 05/19/18 11:52:51 AM
#316   DMSI - most definitely. I see very big pennystockwallstreet 05/19/18 11:50:42 AM
#315   Yes they did put some thought into that. Patient shareholder 05/19/18 11:50:06 AM
#314   Thanks Penny. Goodbuddy4863 05/19/18 11:49:39 AM
#313   DMSI - Welcome to the board as a pennystockwallstreet 05/19/18 11:48:18 AM
#312   I sure think so too. Goodbuddy4863 05/19/18 11:40:45 AM
#311   I would guess there will be much interest Patient shareholder 05/19/18 11:30:36 AM